China Regulatory Changes Benefit Lee/RegeneRx Ophthalmic Alliance
This article was originally published in PharmAsia News
China’s allowance of early clinical trials for drugs sourced outside of the country will help domestic companies develop innovative drugs for the domestic market, as shown by the licensing deal between Lee’s Pharma and RegeneRx for a dry eye syndrome treatment. With the China xerophthalmia segment showing rapid growth, the country may eventually become one of the biggest markets in the world for RGN-259.
Register for our free email digests: